Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in shiraz Namazi hospital multiple myeloma patients

Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in multiple myeloma patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210415050976N16

Enrollment

Registered

2026-03-07

Start date

2026-04-19

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chemotherapy. Antineoplastic chemotherapy induced pancytopenia

Interventions

Intervention 1: Intervention group : patients in this group received a dose of 5 mg olanzapine , along with other anti - nausea standard drugs ( triple regime, dexamethasone and aprpitant/ fosaprpitan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with a known malignant disease (multiple myeloma) are pathologically under chemotherapy Informed written consent Follow-up visits and cooperation

Exclusion criteria

Exclusion criteria: Cognitive disorders, CNS diseases, heart disease and history of diabetes Use of psychotropic medications such as risperidone, quetiapine, clozapine, phenothiazine during treatment Nausea 24 hours before starting olanzapine or chemotherapy Concurrent use of antibiotics such as quinolones Radiotherapy within the past two weeks

Design outcomes

Primary

Measure	Time frame
Nausea and vomiting. Timepoint: From day 1 to day 5 of each treatment. Method of measurement: A daily symptom monitoring checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNavid Kalani

Jahrom University of Medical Sciences

k.navid@jums.ac.ir+98 71 5434 4002

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026